Unapproved GLP-1 Drugs: What to Know About Online Risks

Important note: This article is for general education only. It is not medical, legal, or safety advice. GLP-1 medications require a prescription and medical oversight. Do not start, stop, switch, or buy any medication based on this article. If you have questions about a GLP-1 medication, an online seller, a compounded product, or an investigational drug, talk with your doctor, pharmacist, or another qualified healthcare professional.

GLP-1 access is expanding quickly.

In the UK, the Medicines and Healthcare products Regulatory Agency approved the Wegovy tablet for weight loss and weight management on June 11, 2026. It is the UK’s first GLP-1 receptor agonist tablet for weight management, and it may be prescribed to adults with obesity or to adults with overweight and at least one weight-related condition. The MHRA also notes that the tablet is prescription-only and is not currently available through the NHS.

In the United States, public awareness and use are rising too. A July 2026 Gallup survey found that 11% of U.S. adults reported currently taking a GLP-1 medication for weight loss, up from 3% in 2024. Fifteen percent reported having used one at some point, and 91% said they were aware of the drug class.

More access can be a good thing when it happens through safe, regulated, medically supervised channels.

But fast demand has also created a confusing market: private pharmacy programs, online prescribers, compounded products, counterfeit concerns, and even sellers advertising drugs that have not been approved for any condition.

That is where patients need better guardrails.

Access is growing, but not every source is safe

A prescription medication is not safe simply because it is easy to order.

FDA-approved GLP-1 medications go through review for safety, effectiveness, quality, labeling, manufacturing, and approved uses. That does not mean they are risk-free. It means they have been reviewed under a regulatory process and should be used under medical supervision.

Unapproved versions are different.

The FDA warns that unapproved GLP-1 drugs used for weight loss can be risky because they do not undergo FDA review for safety, effectiveness, or quality before they are marketed.

That distinction matters. A website can look polished. A price can look attractive. A product can use familiar words like “semaglutide,” “tirzepatide,” or “GLP-1.” None of that proves the product is FDA-approved, appropriately prescribed, properly stored, correctly dosed, or safe for a specific person.

Why oral GLP-1s may increase demand

The Wegovy pill is a good example of how access is changing.

For some people, a tablet may feel easier than a weekly injection. It may feel more familiar, less intimidating, or more private. UK reporting noted that the Wegovy pill went on sale through high street and online pharmacies in July 2026, but was not yet available through the NHS.

The pill still has specific instructions. The MHRA says semaglutide tablets should be taken whole on an empty stomach after fasting for at least eight hours, with a sip of water, followed by at least 30 minutes before food or drink. Eating or drinking too soon can lower absorption.

So oral access may reduce one barrier, but it does not remove the need for careful prescribing, instructions, and follow-up.

A pill can be convenient. It is still a prescription medication.

What FDA says about compounded GLP-1 products

Compounded medications are not the same as FDA-approved medications.

The FDA states that compounded drugs are not FDA-approved, which means the agency does not review them for safety, effectiveness, or quality before they are marketed. FDA also says compounded drugs are not the same as generic drugs, which are FDA-approved.

The FDA has raised multiple concerns about compounded GLP-1 products, including dosing errors, fraudulent products, improper storage during shipping, and misleading marketing. FDA has also received reports of adverse events related to compounded semaglutide and tirzepatide, while noting that adverse events are likely underreported because some pharmacies are not required to submit them to FDA.

This is especially important for Glo’s audience.

Glo supports people using doctor-prescribed GLP-1 and GLP-1-related medications. Glo does not support compounded GLP-1 medications or compounded tirzepatide.

If a patient has questions about a compounded product, substitute, supply issue, or medication source, the safest next step is to speak with a licensed prescriber or pharmacist.

Retatrutide is not approved

Retatrutide is getting attention because of strong clinical trial results. Eli Lilly reported that its investigational triple hormone receptor agonist produced 28.3% average weight loss over 80 weeks at the highest dose in the TRIUMPH-1 trial, with a study extension group reaching 30.3% average weight loss at 104 weeks.

But there is a crucial word in that sentence: investigational.

Retatrutide is not FDA-approved as of this article’s publication. It is not an approved medication for weight management, diabetes, or any other condition. It should not be bought online, ordered through informal channels, or used outside appropriate clinical research.

The FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law, and that they are not components of FDA-approved drugs and have not been found safe and effective for any condition.

The FDA has also issued warning letters to companies offering retatrutide online. In a March 31, 2026 warning letter, FDA said a website offering retatrutide for sale in the United States was offering an unapproved new drug. The agency also noted that injectable products can pose serious risks because they bypass some of the body’s defenses against toxins and microorganisms.

A promising trial result is not the same as approval.

Red flags when looking at GLP-1 options online

The FDA lists several warning signs for consumers evaluating online sellers or telehealth platforms. Red flags include companies that claim a compounded drug is the same as an FDA-approved drug, offer prices that seem too good to be true, send medication in damaged or suspicious packaging, fail to require screening and a prescription from a licensed doctor, or do not have a licensed doctor available to answer questions after the medication is received.

Other practical warning signs may include:

No clear pharmacy name.

No state license information.

No meaningful medical intake.

No follow-up plan.

No way to ask clinical questions.

Vague language like “research peptide.”

Claims that a product is “just like” Wegovy, Ozempic, Mounjaro, or Zepbound.

Pressure to buy quickly because of a discount or shortage.

Medication that arrives warm, unlabeled, damaged, or without clear instructions.

A legitimate prescription process should feel like healthcare, not a quick checkout.

Why “generic,” “compounded,” and “research” do not mean the same thing

This is one of the most confusing parts of the GLP-1 market.

A generic drug is FDA-approved and must meet regulatory standards for quality, safety, effectiveness, and equivalence to a reference product.

A compounded drug is made for a specific patient need under certain conditions, but it is not FDA-approved.

A research peptide is not a prescription medication for patient use. Products marketed this way may be attempting to avoid medical or regulatory scrutiny.

An investigational drug is being studied in clinical trials and is not approved for routine patient use unless a specific regulatory pathway applies.

These differences matter because the words can be used loosely in ads, social media, or online forums.

For patients, the question is not “Does the product sound familiar?” The question is: Is this an approved medication, prescribed by a licensed clinician, dispensed by a legitimate pharmacy, and appropriate for my health history?

What patients should ask before using any GLP-1 medication

If you are considering a GLP-1 medication, especially through an online provider, it may help to ask:

Is this medication FDA-approved or approved by the relevant regulator in my country?

Is it prescribed for my specific condition?

Who is the prescribing clinician?

What pharmacy is dispensing it?

Is the pharmacy licensed?

Is this a compounded product?

Is this an investigational drug?

What are the side effects and warning signs?

How do I ask questions after I receive it?

What should I do if it arrives warm, damaged, or unclear?

What follow-up do I need?

If the answer is vague, rushed, or hard to verify, pause and ask a licensed healthcare professional.

Where Glo fits in

Glo is designed to support people using doctor-prescribed GLP-1 and GLP-1-related medications in the day-to-day space between appointments.

Glo can help track meals, hydration, movement, side effects, symptoms, routines, reminders, and questions for a care team. That kind of tracking can make conversations with a doctor, pharmacist, or dietitian more organized.

Glo does not prescribe medication. It does not verify online pharmacies. It does not support compounded GLP-1 medications or compounded tirzepatide. It does not replace a licensed healthcare professional.

As GLP-1 access expands, the goal should not be faster access at any cost. The goal should be safer access, clearer guidance, and better support after treatment begins.

Bottom line

GLP-1 medications are becoming easier to access, and oral options like the Wegovy tablet may make treatment feel more approachable for some people.

But easier access can also create confusion.

FDA-approved medications, compounded products, investigational drugs, counterfeit products, and “research peptides” are not the same. Retatrutide may have promising trial results, but it is not approved. Compounded GLP-1 medications are not FDA-approved. Online sellers can look legitimate while still creating real safety concerns.

The safest path is to use prescription medications through legitimate, medically supervised channels and to bring questions about sourcing, dosing, side effects, and cost to a licensed healthcare professional.

In GLP-1 care, access matters. So do guardrails.